Post by UCL Business Ltd

UK university innovation is firmly on the growth agenda. 🪙 We welcome the announcement from Universities UK’s, who want to unlock £100bn in external investment by 2035, to create jobs, boost economies across the UK and support the government's growth agenda. Spinouts based on world-leading research have high growth potential across many different sectors; but too often, these home-grown innovations are failing to scale into innovative businesses. Here at UCLB, we see what’s possible when the right support and capital come together: -> Autolus Therapeutics: a clinical-stage biopharmaceutical company developing next-generation cell therapies for leukaemia, MS and lupus. Founded in 2014, the company listed on NASDAQ in 2018 and is now a global biotech with a manufacturing centre in Stevenage. -> Phasecraft: a quantum computing company applying advanced algorithms to accelerate real-world applications, showing the commercial potential of deep tech emerging from academia. They raised more than $23 million in a Series A last year. -> Engitix Therapeutics: a platform biotechnology company pioneering extracellular matrix (ECM)-driven drug discovery. They yesterday announced a £44 million strategic research collaboration and option agreement with GSK, to tackle liver fibrosis regression. These UCL spinouts - and many others across the UK - show how breakthrough science can attract investment, grow globally and deliver real-world impact to change the way we live, work and thrive. But scaling consistently, allowing innovation to flourish and keeping companies here in the UK, means we need stronger pathways, deeper partnerships and sustained investor confidence. We support this ambition, which also has the Chancellor's backing, and are excited to see how its realisation supports spinouts and shapes the innovation landscape. Read more from UUK here: https://lnkd.in/d2zNM5Td